Drug Index

Moxifloxacin

 
print

Mechanism :

The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.


Indication :

• Drug resistant tuberculosis

• Bacterial conjunctivitis


Contraindications :

Hypersensitivity, Prolonged QT interval, Hypokalemia, Myasthenia gravis.


Dosing :

Drug resistant tuberculosis:

10-12 mg/kg/day. Max: 400-600 mg/day IV/PO.

Bacterial conjunctivitis:

Put 1 drop of 0.5% ophthalmic solution in each eye 3 times a day for 7 days.


Adverse Effect :

Phototoxicity, superinfection, Clostridium difficile associated diarrhea, seizures, toxic psychosis, depression, suicidal ideation, severe vasculitis, serum sickness, pneumonitis,

myelosuppression, blood dyscrasias, nephrotoxicity, hepatotoxicity, QT prolongation, torsades de pointes, peripheral neuropathy, tendon rupture, arthropathy (animal studies), myasthenia gravis exacerbation, nausea, diarrhea, headache, dizziness, vomiting, constipation.


Interaction :

Acenocoumarol: The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of acenocoumarol.
Aluminium: Formation of non-absorbable complexes.
Amiodarone: Increased risk of cardiotoxicity and arrhythmias.
Anisindione: The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of anisindione.
Artemether: Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Bepridil: Increased risk of cardiotoxicity and arrhythmias.
Bretylium: Increased risk of cardiotoxicity and arrhythmias.
Calcium: Formation of non-absorbable complexes.
Dicoumarol: The quinolone antibiotic, moxifloxacin may increase the anticoagulant effect of dicumarol.
Dihydroquinidine Barbiturate: Increased risk of cardiotoxicity and arrhythmias.
Disopyramide: Increased risk of cardiotoxicity and arrhythmias.
Erythromycin: Increased risk of cardiotoxicity and arrhythmias.
Iron: Formation of non-absorbable complexes.
Iron Dextran: Formation of non-absorbable complexes.
Josamycin: Increased risk of cardiotoxicity and arrhythmias.
Lumefantrine: Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Magnesium: Formation of non-absorbable complexes.
Magnesium Oxide: Formation of non-absorbable complexes.
Quinidine: Increased risk of cardiotoxicity and arrhythmias.
Quinidine barbiturate: Increased risk of cardiotoxicity and arrhythmias.
Quinupristin: This combination presents an increased risk of toxicity.
Sotalol: Increased risk of cardiotoxicity and arrhythmias.
Sucralfate: Formation of non-absorbable complexes.
Tacrolimus: Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution .
Thiothixene: May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
Tizanidine: Moxifloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Toremifene: Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
Trimipramine: Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution .
Voriconazole: Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Vorinostat: Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Warfarin: The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of warfarin.
Zinc: Formation of non-absorbable complexes.
Ziprasidone: Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
Zuclopenthixol: Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes.


07/15/2019 05:40:05 Moxifloxacin
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0